---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-005548"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-04-10T23:59:59+00:00"
generated_at: "2026-06-17T04:15:35.246214+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sana appoints Douglas Williams as President of R&D and Gary Meininger as CMO; CMO Sunil Agarwal departs

## Summary
- Douglas Williams, Ph.D., appointed EVP & President, R&D effective April 10, 2023; previously CEO of Codiak BioSciences.
- Gary Meininger, M.D., appointed Chief Medical Officer; previously SVP, Head of Clinical Development at Vertex.
- Sunil Agarwal, M.D., resigns as CMO effective April 10, 2023; will remain employee through April 28 for transition.
- Williams receives $580,000 base salary, 40% target bonus, and option to purchase 1,100,000 shares of common stock.

## SEC filing metadata
- accession: 0001564590-23-005548
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000156459023005548/0001564590-23-005548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000156459023005548/sana-8k_20230410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-005548
- JSON: https://secwatch.observer/filing/0001564590-23-005548.json
- Plain text: https://secwatch.observer/filing/0001564590-23-005548.txt

## Key facts
- Executive change
  Sunil Agarwal resigned as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc..
  - Action: resigned
  - Role: Executive Vice President, Head of Development, and Chief Medical Officer
  source text: Sunil Agarwal, M.D. resigned from his position as Executive Vice President, Head of Development, and Chief Medical Officer of the Company, effective as of April 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000156459023005548/0001564590-23-005548-index.htm
- Executive change
  Douglas E. Williams was appointed as Executive Vice President and President, Research and Development at Sana Biotechnology, Inc..
  - Action: appointed
  - Role: Executive Vice President and President, Research and Development
  source text: Douglas E. Williams, Ph.D., has been appointed and will join the Company as Executive Vice President and President, Research and Development, effective April 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000156459023005548/0001564590-23-005548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.